enGene Therapeutics Inc. (ENGN)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript
enGene Holdings Inc. ( ENGN ) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC November 11, 2025 8:00 AM EST Company Participants Lauren Hopfer Ronald H. Cooper - President, CEO & Director Hussein Sweiti - Chief Medical Officer Conference Call Participants Suzanne Merrill Yanan Zhu - Wells Fargo Securities, LLC, Research Division Judah Frommer - Morgan Stanley, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Andres Maldonado - H.C.
EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (NASDAQ:ENGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Ronald H. Cooper - President, CEO & Director Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Welcome to the session of the Morgan Stanley Global Healthcare Conference.
enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)
enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in the near term. While regulatory discussions are encouraging, the investment thesis hinges on positive LEGEND trial results, making this a high-risk, high-reward scenario.
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch
enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential.
Best Momentum Stocks to Buy for February 19th
NVMI, FRSH and ENGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19, 2024.
New Strong Buy Stocks for February 19th
GE, OPRT, ENGN, FRSH and NVMI have been added to the Zacks Rank #1 (Strong Buy) List on February 19, 2024.
How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77%
The average of price targets set by Wall Street analysts indicates a potential upside of 238.8% in enGene Holdings Inc. (ENGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why
enGene Holdings Inc. (ENGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook
enGene is working toward an approval similar to what IBRX got with Anktiva, although without needing BCG co-administration. NMIBC remains an area of unmet need, although it may not be SO unmet that the FDA gives ENGN a generous approval on single-arm data. Considering the current price, and their favorable financial position, my outlook from here for the company is very positive.
Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks
enGene Holdings Inc. (ENGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
